Hansen Pharmaceutical(SZ:002412)2023-06-20 13:10Group 1: Product Performance - The revenue of the product "Simiao Decoction Oral Liquid" in 2022 was 533 million CNY, representing a year-on-year growth of 8.1% [1] - "Simiao Decoction Oral Liquid" is the only compound gastrointestinal motility traditional Chinese medicine product on the market, enhancing gastrointestinal motility and digestion, with dual regulation effects on constipation and diarrhea [1] Group 2: Future Product Planning - The company plans to increase the promotion of "Simiao Decoction Oral Liquid" to establish brand image and boost sales growth [1] - The company has developed a strategy for intellectual property protection to safeguard exclusive product patents and will continue to invest in technology and processes [2] Group 3: Product Portfolio and Market Strategy - The company has maintained stable growth through acquisitions, forming a product system focused on digestive and cardiovascular medications [2] - The product structure is reasonable and diverse, which helps mitigate operational risks associated with reliance on a single product, enhancing profitability and risk resistance [2] Group 4: Regulatory and Market Positioning - The company is actively monitoring policy changes regarding the inclusion of "Simiao Decoction Oral Liquid" in the essential drug list and aims to meet the evaluation standards for inclusion [2] - The company is developing potential products with local characteristics, such as "Tianma Xingnao Capsule," leveraging regional advantages [2]